Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients

EJHaem Pub Date : 2025-03-04 DOI:10.1002/jha2.70012

Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Sören Twarock, Stefanie Geyh, Kathrin Nachtkamp, Patrick Tressin, Annika Kasprzak, Felix Matkey, Titus Watrin, Malika El Yaouti, Ulrich Germing, Sascha Dietrich, Guido Kobbe

{"title":"Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients","authors":"Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Sören Twarock, Stefanie Geyh, Kathrin Nachtkamp, Patrick Tressin, Annika Kasprzak, Felix Matkey, Titus Watrin, Malika El Yaouti, Ulrich Germing, Sascha Dietrich, Guido Kobbe","doi":"10.1002/jha2.70012","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In a cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.</p>\n </section>\n \n <section>\n \n <h3> Clinical trial registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70012","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.

Results

In a cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.

Conclusion

These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.

Clinical trial registration

The authors have confirmed clinical trial registration is not needed for this submission.

Abstract Image

查看原文本刊更多论文

单倍体同种异体干细胞移植作为错配供体患者的优越选择- 152例患者的单中心经验

背景：同种异体造血干细胞移植（allogene hematopoietic stem cell transplantation, alloo - sct）是治疗恶性血液病的关键方法，但供体选择影响结果。在2012年至2023年接受同种异体sct的152例患者中，移植后使用环磷酰胺（PTCy）的单倍体相同供体比9/10不匹配的非亲属供体（MMUD）的生存率更高。Cox回归分析显示，移植前未完全缓解（CR）的患者特别受益于单倍体供体，而9/10 MMUD和缺乏CR的患者预后更差。结论这些结果强调了供体选择的重要性，提示对于非CR患者，单倍体PTCy供体可能更可取，其他患者需要选择其他途径。临床试验注册作者已确认该提交不需要临床试验注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量